Cullinan Therapeutics, Inc. - 8-K Filing

Cullinan Therapeutics announces updated Phase 1 clinical data for CLN-049 in AML/MDS and upcoming ASH meeting presentations. (Items: 7.01 Regulation FD Disclosure, 8.01 Other Events, 9.01 Financial Statements and Exhibits)

3 articles from 1 source · updated November 4, 2026, 21:02 UTC

Coverage

• Damora Therapeutics, Inc. - 10-Q Filing SEC EDGAR · November 4, 2026, 21:00 UTC
• Seres Therapeutics, Inc. - 10-Q Filing SEC EDGAR · November 4, 2026, 15:00 UTC
• Cullinan Therapeutics, Inc. - 8-K Filing SEC EDGAR · November 4, 2026, 14:17 UTC